OR WAIT 15 SECS
The partners will use ProBioGen’s DirectedLuck transposase technology to support development and large-scale manufacturing of ImmunOs’ biologics.
ProBioGen, a German contract development and manufacturing organization that specializes in developing complex antibodies and glycoproteins, and the Swiss biotechnology company, ImmunOs Therapeutics, a spinoff of the Universities of Zurich and Basel, have established a development and manufacturing agreement. Under its terms, the partners will use ProBioGen’s DirectedLuck transposase technology , as well as its CHO.RiGHTT expression and manufacturing platform, to develop ImmunOs’ pipeline of novel biologics, which focus on human immunomodulatory proteins that activate anti-tumor responses. They will also work on large-scale good manufacturing practices (GMP) manufacturing.
“We are pleased about this confidence in our expertise. It is our goal [to] enable[e] ImmunOs to start clinical trials with this promising molecule in a timely manner. We are very passionate to develop a cell line and robust processes based on our innovative technologies to deliver their product with highest quality,” said Dr. Wieland Wolf, CEO of ProBioGen, in a press release that was issued on February 20, 2020.